Testosterone Enanthate and Tadalafil Interaction: Safety, Risks, and Clinical Guidance

Why These Two Drugs Are Frequently Co-Prescribed

Testosterone replacement therapy (TRT) and PDE5 inhibitors rank among the most common combination regimens in men's health clinics. The reason is straightforward: hypogonadism and erectile dysfunction (ED) share overlapping pathophysiology, and treating one condition often does not fully resolve the other.

A 2015 meta-analysis in the Journal of Sexual Medicine pooling 14 randomized controlled trials (N = 2,029) found that testosterone therapy alone improved International Index of Erectile Function (IIEF) scores by a mean of 2.95 points, a statistically significant but clinically modest gain [1]. Among men with both low testosterone and ED, roughly 35% still reported inadequate erections after testosterone normalization [2]. That residual ED is where tadalafil fills the gap. The TADTEST trial demonstrated that the combination of testosterone undecanoate plus tadalafil 20 mg produced significantly greater IIEF-EF domain improvements than either agent alone in hypogonadal men with ED (mean IIEF-EF increase of 8.5 vs. 3.9 for testosterone monotherapy, P<0.001) [3].

These data explain why prescribers routinely pair the two. The clinical question is whether co-administration introduces pharmacologic risk.

Pharmacokinetic Profile: No Meaningful CYP Conflict

Testosterone enanthate is an intramuscular depot formulation. After injection, esterases in the blood cleave the enanthate ester to release free testosterone. That free testosterone then undergoes hepatic metabolism primarily via CYP3A4 and to a lesser extent via CYP19A1 (aromatase) to estradiol, and via 5-alpha reductase to dihydrotestosterone (DHT) [4]. Testosterone is not a significant inhibitor or inducer of any CYP isoform at physiologic or supraphysiologic replacement doses.

Tadalafil is a CYP3A4 substrate. Its 17.5-hour half-life and steady-state pharmacokinetics are well characterized in the FDA prescribing information [5]. Strong CYP3A4 inhibitors (ketoconazole, ritonavir) increase tadalafil AUC by up to 312%, which is why dose capping at 10 mg per 72 hours is recommended with potent inhibitors [5].

Testosterone does not inhibit CYP3A4. A 2006 in vitro study by Kamdem et al. confirmed that testosterone concentrations up to 100 micromolar produced no clinically relevant inhibition of CYP3A4-mediated midazolam hydroxylation [6]. At standard TRT doses of 100 to 200 mg every one to two weeks, peak serum testosterone rarely exceeds 0.035 micromolar, orders of magnitude below any inhibitory threshold.

The P-glycoprotein (P-gp) transporter is also not a concern. Tadalafil is not a recognized P-gp substrate, and testosterone does not modulate P-gp activity at clinical concentrations [5][7]. The bottom line: these two drugs do not compete for metabolic clearance, and neither alters the other's plasma levels.

Pharmacodynamic Interactions: Where Clinical Attention Belongs

The absence of a pharmacokinetic interaction does not mean zero overlap. Both drugs exert vascular and hematologic effects that can be additive.

Blood Pressure and Hemodynamics

Tadalafil produces mild systemic vasodilation by preventing cGMP degradation in vascular smooth muscle. The FDA label reports a mean reduction of 1.6/0.8 mmHg in healthy volunteers at the 20 mg dose [5]. Testosterone, through its conversion to estradiol and direct effects on vascular endothelial nitric oxide synthase (eNOS), can also modestly lower peripheral resistance in some men while raising it in others depending on baseline erythrocytosis and fluid retention [8].

The 2018 Endocrine Society Clinical Practice Guideline states: "Clinicians should monitor blood pressure within 3 to 6 months after initiating testosterone therapy, as fluid retention may raise blood pressure in susceptible individuals" [9]. When tadalafil is added, blood pressure monitoring becomes doubly relevant. The combination has not been associated with clinically significant hypotension in any published trial, but men taking alpha-blockers or antihypertensives alongside both agents should check seated and standing blood pressure at each follow-up visit.

Erythrocytosis

This is the highest-yield safety concern. Testosterone stimulates erythropoiesis through suppression of hepcidin and direct stimulation of erythroid progenitors [10]. The Testosterone Trials (TTrials, N = 790) reported that 8.5% of men on transdermal testosterone gel developed a hematocrit above 54% within 12 months, compared to 1.0% in the placebo group [11].

Tadalafil does not independently raise hematocrit. It does not worsen testosterone-induced erythrocytosis through any known mechanism. The concern is indirect: if a clinician attributes good symptom control to tadalafil and delays hematocrit monitoring that should have been triggered by the testosterone prescription, a dangerously elevated hematocrit could go undetected.

The Endocrine Society guideline recommends checking hematocrit at baseline, 3 to 6 months after starting TRT, and annually thereafter [9]. Any value above 54% should prompt dose reduction, injection frequency adjustment, or therapeutic phlebotomy.

Cardiovascular Risk

The TRAVERSE trial (N = 5,246), published in the New England Journal of Medicine in 2023, provided the first large-scale randomized data on cardiovascular safety of testosterone in men aged 45 to 80 with hypogonadism and pre-existing or high risk for cardiovascular disease. The primary composite endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) occurred in 7.0% of the testosterone group versus 7.3% of the placebo group (HR 0.96 to 95% CI 0.78 to 1.17), establishing non-inferiority [12].

Tadalafil's cardiovascular profile is similarly reassuring. A pooled analysis of 26 tadalafil trials reported no increase in major adverse cardiovascular events (MACE) relative to placebo [13]. The combination has not been studied in a dedicated cardiovascular outcomes trial, but the independent safety signals from TRAVERSE and the tadalafil pooled data reduce concern.

The one absolute contraindication involving tadalafil is concurrent nitrate use. Tadalafil plus any organic nitrate (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) can cause severe, potentially fatal hypotension [5]. Testosterone does not interact with nitrates, but any man prescribed both testosterone and tadalafil who later requires nitrate therapy for angina must discontinue the PDE5 inhibitor. As the FDA label states: "Administration of tadalafil to patients who are using any form of organic nitrate is contraindicated. In a patient who has taken tadalafil, where nitrate administration is deemed medically necessary in a life-threatening situation, at least 48 hours should elapse after the last dose of tadalafil before nitrate administration is considered" [5].

Dose Adjustments and Prescribing Considerations

No dose modification of testosterone enanthate is required when tadalafil is added. No dose modification of tadalafil is required when testosterone enanthate is used concurrently.

Standard dosing remains:

Testosterone enanthate: 100 to 200 mg intramuscular injection every 7 to 14 days for TRT. The FDA-approved labeling for Delatestryl specifies individualized dosing based on age, sex, diagnosis, and therapeutic response, with the typical male hypogonadism range of 50 to 400 mg every 2 to 4 weeks [4].

Tadalafil: For ED, 10 mg as needed (may adjust to 20 mg or 5 mg); for daily use, 2.5 to 5 mg once daily. For BPH or combined ED/BPH, 5 mg daily [5].

When prescribing both:

1. Start testosterone first and reassess erectile function at 8 to 12 weeks (allowing time for steady-state testosterone levels).
2. If ED persists after testosterone normalization, add tadalafil at the lowest effective dose.
3. Avoid reflexive up-titration of tadalafil before confirming testosterone levels are in the therapeutic range (typically 400 to 700 ng/dL trough).
4. Confirm the patient is not taking nitrates, alpha-blockers at unstable doses, or potent CYP3A4 inhibitors that would require tadalafil dose capping.

Monitoring Protocol for the Combination

A structured follow-up schedule reduces the risk of missing additive adverse effects.

Baseline (before starting either drug): Complete blood count (CBC) with hematocrit, comprehensive metabolic panel, fasting lipid panel, total and free testosterone (drawn between 7:00 and 10:00 AM), PSA (in men over 40), and blood pressure.

3 months after starting testosterone enanthate: Repeat CBC (hematocrit is the priority value), total testosterone trough (drawn just before the next injection), liver function, and blood pressure. If tadalafil was started concurrently, ask about orthostatic symptoms.

6 months: Repeat CBC, lipid panel, PSA, blood pressure. Assess erectile function with a validated instrument (IIEF-5 or SHIM).

Annually thereafter: Full panel as at 6 months, plus DXA if osteoporosis was part of the indication.

The American Urological Association's 2018 guideline on testosterone therapy echoes this cadence and adds: "Clinicians should inform patients of the absence of evidence linking testosterone therapy to the development of prostate cancer" [14], a counseling point that reduces unnecessary anxiety when adding a second medication to an already-apprehensive patient.

Drug Interactions Beyond Tadalafil: What Else to Watch

Men on testosterone enanthate are often on additional medications. A brief survey of the most clinically relevant interactions:

Warfarin and anticoagulants. Testosterone may increase the effect of warfarin by enhancing synthesis of clotting factors and altering protein binding. The FDA label for Delatestryl warns that "concurrent use of testosterone with oral anticoagulants may require a decrease in the dose of the anticoagulant" [4]. INR monitoring should be intensified for the first 4 weeks of TRT in warfarin-treated men.

Insulin and oral hypoglycemics. Testosterone improves insulin sensitivity. A 2016 RCT by Dhindsa et al. (N = 94) showed that testosterone therapy in hypogonadal men with type 2 diabetes reduced HOMA-IR by 15.2% over 24 weeks [15]. Hypoglycemia risk may increase if oral agents or insulin doses are not adjusted.

Corticosteroids. Concurrent use may increase fluid retention. Edema risk is additive.

CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin). These do not significantly affect testosterone (which is a CYP3A4 substrate at a minor pathway level), but they substantially raise tadalafil exposure. If a man on both testosterone and tadalafil starts a strong CYP3A4 inhibitor, the tadalafil dose should be capped at 10 mg every 72 hours for as-needed use, or avoided entirely for the daily regimen [5].

Patient Counseling Points

Three things every patient taking both drugs should hear:

First, the two medications work through completely separate mechanisms. Testosterone replaces a deficient hormone. Tadalafil increases the downstream signaling of nitric oxide already present in penile erectile tissue. They are complementary, not redundant, and both may be necessary to fully restore function.

Second, tadalafil must never be taken with nitrate medications. This includes nitroglycerin tablets, patches, sprays, and isosorbide preparations. If chest pain occurs and the patient goes to an emergency department, they must tell the treating physician they take tadalafil so that nitrates are withheld for at least 48 hours after the last dose.

Third, blood draws matter. Hematocrit monitoring is not optional while on testosterone. A hematocrit above 54% raises the risk of venous thromboembolism, and this threshold can be reached within 3 to 6 months of starting TRT [9]. Skipping labs puts the patient at avoidable risk.

The target hematocrit that should trigger phlebotomy or dose reduction is 54%, as specified by the Endocrine Society guideline authored by Bhasin et al. (2018): "If hematocrit rises above 54%, stop testosterone therapy and evaluate the patient for hypoxia and sleep apnea; restart at a lower dose after hematocrit has decreased to a safe level" [9].